APO-CANDESARTAN: Affected lots were manufactured using an active ingredient that was out of specification for dissolution
Brand(s)
Last updated
Summary
Product
APO-CANDESARTAN
Issue
Health products - Product quality
What to do
Consult your health care professional if you have any health concerns.
Distribution
National
Affected products
Brand |
Product Name |
Market Authorization |
Dosage Form |
Strength |
Lot Number |
|---|---|---|---|---|---|
APOTEX INC |
APO-CANDESARTAN TABLETS |
DIN 02541297 |
Tablet |
CANDESARTAN CILEXETIL/ 8MG |
PTG0761A |
APOTEX INC |
APO-CANDESARTAN TABLETS |
DIN 02541300 |
Tablet |
CANDESARTAN CILEXETIL/16MG |
PTF5493B, PTG1028A |
Issue
Affected lots were manufactured using an active ingredient that was out of specification for dissolution.
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Retailers, Wholesalers, Pharmacies
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
| APOTEX INC 150 Signet Drive Toronto, ON M9L 1T9 |
Published by
Health Canada
Audience
General public
Healthcare
Industry
Distribution
National
Recall class
Type II
Identification number
RA-81606
Get notified
Receive emails about new and updated recall and safety alerts.